Skip to content

Effectiveness of HVNI in Preterm Infants With Moderate Respiratory Distress

Effectiveness of High Velocity Nasal Insufflation (HVNI) in Infants <32 Weeks Gestational Age(GA) or Birth Weight <1500 Grams With Moderate Respiratory Distress in Dr.Cipto Mangunkusumo Hospital

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06436222
Enrollment
60
Registered
2024-05-31
Start date
2024-05-20
Completion date
2024-12-31
Last updated
2024-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Distress, Newborn

Brief summary

Neonatal respiratory distress is a common problem in preterm infants. The application of CPAP is widely used in neonatal units as a primary mode of respiratory support for respiratory distress. However, discomfort, nasal injuries, and fixation difficulties have been reported as obstacles when applying CPAP. High velocity nasal insufflation (HVNI) may serve as an alternative to CPAP. Trials are needed to evaluate the effectiveness of HVNI in reducing the incidence of respiratory distress. The aim of this study is to compare the clinical effectiveness and safety of HVNI as an alternative therapy to CPAP in premature infants with moderate respiratory distress. This study is a prospective, non-inferiority, randomized, unblinded controlled trial to compare the efficacy of HVNI and CPAP. The subjects were randomly allocated to receive either HVNI or CPAP according to the study protocol. They were randomly assigned using blocks of four. The completion of HVNI therapy was determined by therapeutic failure within 72 hours following enrollment, indicated by the need for intubation.

Interventions

DEVICEHVNI

Preterm infants with gestational age (GA) less than 32 weeks or birth weight less than 1500 grams. The infant has moderate respiratory distress (Downe score ≤ 6) detected within 24 hours after birth.

Sponsors

Indonesia University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

Participants are assigned to two groups either HVNI (intervention group) or CPAP (control group)

Eligibility

Sex/Gender
ALL
Age
28 Weeks to 32 Weeks
Healthy volunteers
Yes

Inclusion criteria

\*\*Inclusion Criteria:\*\* * Preterm infants born in Cipto Mangunkusumo Hospital with gestational age (GA) less than 32 weeks or birth weight less than 1500 grams. * Infants with moderate respiratory distress (Downe score ≤ 6) detected within 24 hours after birth. * Parents are willing to participate in the study. \*\*

Exclusion criteria

\*\* * Infants with severe respiratory distress (Downe score ≥ 6) requiring invasive treatment in the form of mechanical ventilation, or apnea indicated by surfactant administration via endotracheal tube. * Infants with contraindications to the use of non-invasive ventilation such as esophageal atresia, diaphragmatic hernia, air leak syndrome, and other conditions. * Infants with respiratory distress due to non-pulmonary abnormalities. * Infants with congenital metabolic disorders. * Infants with congenital abnormalities that exacerbate respiratory distress.

Design outcomes

Primary

MeasureTime frameDescription
Effectiveness of HVNI to prevent intubation within 72 hoursIntubation rates within 72 hoursThe primary outcome was treatment failure/success within 72 hours of treatment between HVNI and CPAP

Secondary

MeasureTime frameDescription
Length of stay30 daysDuration from birth until discharge

Other

MeasureTime frameDescription
Intraventricular Hemmorhage (IVH)one weekThe occurrence of bleeding in lateral and third or fourth ventricles characterized by hyper-attenuating fluid typically seen as layering within the ventricles in imaging studies
Bronchopulmonary Dysplasia (BPD)Within 28 daysProlonged need for supplemental oxygen in preterm infants after 28 days of age or after 36 weeks postmenstrual age and who do not have other conditions requiring oxygen

Contacts

Primary ContactPutri Maharani Tristanita Marsubrin, MD, PhD
putristanita2806@yahoo.com+62 812-8126-640

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026